WO2005044977A3 - Compositions, splice variants and methods relating to lung specific genes and proteins - Google Patents

Compositions, splice variants and methods relating to lung specific genes and proteins Download PDF

Info

Publication number
WO2005044977A3
WO2005044977A3 PCT/US2004/020678 US2004020678W WO2005044977A3 WO 2005044977 A3 WO2005044977 A3 WO 2005044977A3 US 2004020678 W US2004020678 W US 2004020678W WO 2005044977 A3 WO2005044977 A3 WO 2005044977A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
compositions
lung
antagonists
agonists
Prior art date
Application number
PCT/US2004/020678
Other languages
French (fr)
Other versions
WO2005044977A2 (en
Inventor
Steffan F Vartanian
Leah R Turner
Roberto A Macina
Huei-Mei Chen
Albert Tam
Original Assignee
Diadexus Inc
Steffan F Vartanian
Leah R Turner
Roberto A Macina
Huei-Mei Chen
Albert Tam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc, Steffan F Vartanian, Leah R Turner, Roberto A Macina, Huei-Mei Chen, Albert Tam filed Critical Diadexus Inc
Publication of WO2005044977A2 publication Critical patent/WO2005044977A2/en
Publication of WO2005044977A3 publication Critical patent/WO2005044977A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic lung cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating lung cancer and non-cancerous disease states in lung, identifying lung tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered lung tissue for treatment and research.
PCT/US2004/020678 2003-06-25 2004-06-25 Compositions, splice variants and methods relating to lung specific genes and proteins WO2005044977A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48246103P 2003-06-25 2003-06-25
US60/482,461 2003-06-25
US48458303P 2003-06-30 2003-06-30
US60/484,583 2003-06-30

Publications (2)

Publication Number Publication Date
WO2005044977A2 WO2005044977A2 (en) 2005-05-19
WO2005044977A3 true WO2005044977A3 (en) 2009-03-26

Family

ID=34576512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020678 WO2005044977A2 (en) 2003-06-25 2004-06-25 Compositions, splice variants and methods relating to lung specific genes and proteins

Country Status (1)

Country Link
WO (1) WO2005044977A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225103B1 (en) * 1996-11-20 2001-05-01 Oklahoma Medical Research Foundation Cloning and characterization of napsin
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225103B1 (en) * 1996-11-20 2001-05-01 Oklahoma Medical Research Foundation Cloning and characterization of napsin
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATNELL ET AL.: "Napsins: New Human Aspartic Proteinases Distinction between two closely related genes", FEBS LETTERS, vol. 44, 11 December 1998 (1998-12-11), pages 43 - 48 *

Also Published As

Publication number Publication date
WO2005044977A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2004092338A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002064741A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2003106648A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2007001399A3 (en) Compositions, splice variants and methods relating to cancer specific genes and proteins
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004053077A3 (en) Compositions,splice variants and methods relating to breast specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003020953A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2004053081A3 (en) Compositions, splice variants and methods relating to prostate specific genes and proteins
WO2002068645A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2004074430A3 (en) Compositions, splice variants and methods relating to lung specific genes and proteins
WO2002046224A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003060121A3 (en) Compositions and methods relating to gastric specific genes and proteins
WO2003060081A3 (en) Compositions and methods relating to endometrial specific genes and proteins
WO2003055982A3 (en) Compositions and methods relating to endometrial specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase